EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Cardiovascular and renal outcomes with varying degrees of kidney disease in high‐risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE‐O trial

Hertzel C Gerstein iD, Rajibul Mian, Chinthanie Ramasundarahettige, Kelley R H Branch, Stefano Del Prato iD, Carolyn S P Lam iD, Renato D Lopes, Richard Pratley, Julio Rosenstock iD, Naveed Sattar iD

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15417 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Hertzel C Gerstein und 9 weiteren Autor:innen. Beteiligte Einrichtung: Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Kidney Diseases, Cardiovascular System, Cardiovascular Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Hanmi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To estimate the incidence of a major adverse cardiovascular event (MACE) and a composite kidney outcome across estimated glomerular filtration rate (eGFR) and urine albumin‐to‐creatinine ratio (UACR) levels, and to determine whether efpeglenatide's effect varies with these indices. Materials and Methods AMPLITUDE‐O trial data were used to estimate the relationship of eGFR, UACR, and Kidney Disease Improving Global Outcomes (KDIGO) category to the hazard of MACE and the kidney composite. Interactions on these outcomes between eGFR and the UACR, and between each of these variables and efpeglenatide were also assessed.

Results

Baseline eGFR and UACR were available for 3983 participants (mean age 64.5 years). During a median follow‐up of 1.8 years, the hazards of MACE and the kidney composite for the lowest versus highest eGFR third were 1.6 (95% confidence interval [CI] 1.2, 2.2) and 2.3 (95% CI 1.9, 2.8), respectively. The hazards for the highest versus the lowest UACR third were 2.3 (95% CI 1.8, 3.1) and 18.0 (95% CI 12.7, 25.5), respectively, and for the high‐ versus low‐risk KDIGO categories the hazards were 2.4 (95% CI 1.8, 3.1) and 16.0 (95% CI 11.6, 22.0), respectively. eGFR and UACR were independent determinants of both outcomes, but negatively interacted with each other for the kidney outcome. Efpeglenatide's effect on both outcomes did not vary with any kidney disease measure (all interaction p values ≥0.26).

Conclusions

In high‐risk people with diabetes, eGFR, UACR, and KDIGO category have different relationships to incident cardiovascular and kidney outcomes. The beneficial effect of efpeglenatide on these outcomes is independent of kidney‐related risk category.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Kidney DiseasesCardiovascular SystemCardiovascular DiseasesHumansMiddle AgedKidneyGlomerular Filtration RateAlbuminuriaCreatinine

Stichwörter der Autor:innen

GLP-1 analoguecardiovascular diseasekidney diseaserandomized trialtype 2 diabetes

Substanzen

Creatinine

Autor:innen und Institutionen

  • Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.
  • Department of Medicine, Master University, Hamilton, Ontario, Canada.
  • Division of Cardiology, University of Washington, Seattle, Washington, USA.
  • Interdisciplinary Research Center "Health Science" of the Sant'Anna School of Advanced Studies, Pisa, Italy.
  • National Heart Centre Singapore and Duke-National University of Singapore, Singapore, Singapore.
  • Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA.

ORCID-Profile: Hertzel C Gerstein, Stefano Del Prato, Carolyn S P Lam, Julio Rosenstock, Naveed Sattar

Förderung

  • Hanmi

Zitieren

APA

Gerstein, H. C., Mian, R., Ramasundarahettige, C., Branch, K. R. H., Del Prato, S., Lam, C. S. P., Lopes, R. D., Pratley, R., Rosenstock, J., & Sattar, N. (2024). Cardiovascular and renal outcomes with varying degrees of kidney disease in high‐risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE‐O trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15417

Vancouver

Gerstein HC, Mian R, Ramasundarahettige C, Branch KRH, Del Prato S, Lam CSP, et al. Cardiovascular and renal outcomes with varying degrees of kidney disease in high‐risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE‐O trial. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15417

BibTeX
@article{Gerstein2024,
  author = {Gerstein, Hertzel C and Mian, Rajibul and Ramasundarahettige, Chinthanie and Branch, Kelley R H and Del Prato, Stefano and Lam, Carolyn S P and Lopes, Renato D and Pratley, Richard and Rosenstock, Julio and Sattar, Naveed},
  title = {Cardiovascular and renal outcomes with varying degrees of kidney disease in high‐risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE‐O trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15417}
}
Kostenlos starten →